Research Analysts Offer Predictions for SLNO Q2 Earnings

Soleno Therapeutics, Inc. (NASDAQ:SLNO) – HC Wainwright boosted their Q2 2026 earnings per share estimates for Soleno Therapeutics in a research note issued on Tuesday, January 20th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of $1.00 per share for the quarter, up from their prior forecast of $0.85. HC Wainwright currently has a “Buy” rating and a $120.00 price target on the stock. The consensus estimate for Soleno Therapeutics’ current full-year earnings is ($3.72) per share. HC Wainwright also issued estimates for Soleno Therapeutics’ Q3 2026 earnings at $1.24 EPS and Q4 2026 earnings at $1.70 EPS.

Soleno Therapeutics (NASDAQ:SLNO) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $0.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.08 by $0.39. The business had revenue of $66.02 million for the quarter, compared to analysts’ expectations of $47.46 million.

SLNO has been the topic of a number of other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Soleno Therapeutics in a research note on Wednesday, October 8th. Zacks Research upgraded Soleno Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday, January 5th. Wall Street Zen raised shares of Soleno Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Robert W. Baird set a $107.00 target price on shares of Soleno Therapeutics in a report on Tuesday, January 13th. Finally, Wells Fargo & Company reissued an “overweight” rating and set a $114.00 price target (up from $106.00) on shares of Soleno Therapeutics in a report on Tuesday. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $110.62.

Soleno Therapeutics Stock Up 0.4%

SLNO stock opened at $43.75 on Wednesday. The company has a market capitalization of $2.35 billion, a P/E ratio of -23.78 and a beta of -3.12. Soleno Therapeutics has a 12 month low of $39.43 and a 12 month high of $90.32. The firm’s fifty day simple moving average is $47.25 and its 200-day simple moving average is $61.57. The company has a debt-to-equity ratio of 0.10, a current ratio of 16.08 and a quick ratio of 15.88.

Hedge Funds Weigh In On Soleno Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Raymond James Financial Inc. purchased a new position in Soleno Therapeutics during the second quarter valued at $25,000. Danske Bank A S acquired a new stake in Soleno Therapeutics in the 3rd quarter worth about $27,000. Nisa Investment Advisors LLC boosted its holdings in Soleno Therapeutics by 287.8% in the 2nd quarter. Nisa Investment Advisors LLC now owns 539 shares of the company’s stock worth $45,000 after buying an additional 400 shares during the last quarter. Aster Capital Management DIFC Ltd purchased a new stake in Soleno Therapeutics during the 3rd quarter worth approximately $37,000. Finally, Quarry LP acquired a new position in shares of Soleno Therapeutics during the third quarter valued at approximately $47,000. 97.42% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Soleno Therapeutics

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: HC Wainwright materially raised EPS forecasts across 2025–2026 (Q4‑2025, Q1‑2026, full‑year 2025 and 2026 and quarterly 2026 guidance) and reiterated a “Buy” rating with a $120 price target — the firm now models FY2026 EPS of $4.82, up sharply from prior estimates, signaling an expectation of rapid revenue/profit growth that supports higher valuation. HC Wainwright raises estimates (MarketBeat)
• Positive Sentiment: Cantor Fitzgerald reiterated an Overweight rating and set a $123 price target after citing that Soleno’s Vykat has captured roughly 12.5% market share in Prader‑Willi Syndrome — market‑share gains for a specialty orphan drug are a clear revenue catalyst and justify higher forward multiples. Soleno Therapeutics Inc. (SLNO): Analysts See Major Upside
• Neutral Sentiment: Despite these upgrades, consensus estimates still show a negative EPS for the current fiscal year (consensus ~‑$3.72); analysts’ upgrades reflect rapid expected improvement but also introduce execution risk—stock performance will depend on continued uptake of Vykat and whether results match the newly raised projections. SLNO company page (MarketBeat)

About Soleno Therapeutics

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.